N D Wood, M Aitken, S Durston, S Harris, G R McClelland, S Sharp
{"title":"软骨保护剂(CPA) Ro 32-3555，一种治疗类风湿关节炎的新型基质金属蛋白酶抑制剂。","authors":"N D Wood, M Aitken, S Durston, S Harris, G R McClelland, S Sharp","doi":"10.1007/978-3-0348-8857-8_8","DOIUrl":null,"url":null,"abstract":"<p><p>CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC0-infinity and Cmax. Administration of 10 mg CPA following food resulted in a delayed tmax, and a significant decrease in Cmax but not AUC0-infinity.</p>","PeriodicalId":7491,"journal":{"name":"Agents and actions. Supplements","volume":"49 ","pages":"49-55"},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.\",\"authors\":\"N D Wood, M Aitken, S Durston, S Harris, G R McClelland, S Sharp\",\"doi\":\"10.1007/978-3-0348-8857-8_8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC0-infinity and Cmax. Administration of 10 mg CPA following food resulted in a delayed tmax, and a significant decrease in Cmax but not AUC0-infinity.</p>\",\"PeriodicalId\":7491,\"journal\":{\"name\":\"Agents and actions. Supplements\",\"volume\":\"49 \",\"pages\":\"49-55\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Agents and actions. Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/978-3-0348-8857-8_8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Agents and actions. Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-0348-8857-8_8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.
CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC0-infinity and Cmax. Administration of 10 mg CPA following food resulted in a delayed tmax, and a significant decrease in Cmax but not AUC0-infinity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
